267 related articles for article (PubMed ID: 10934306)
1. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.
Xhignesse M; Laplante P; Niyonsenga T; Courteau J; Grant AM
Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: are we doing enough?
Xhignesse M; Laplante P; Grant AM; Niyonsenga T; Delisle E; Vanasse N; Bernier R
Can J Cardiol; 1999 Feb; 15(2):185-9. PubMed ID: 10079778
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
Petrella RJ; Merikle E; Jones J
Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
[TBL] [Abstract][Full Text] [Related]
4. Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators.
Oriol-Zerbe C; Abholz HH
Eur J Gen Pract; 2007; 13(1):27-34. PubMed ID: 17366291
[TBL] [Abstract][Full Text] [Related]
5. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
6. [Great discrepancies between European, Dutch and Belgian criteria for the use of statins in the prevention of primary cardiovascular disease in family practice].
Van Diest E; Stoffelen E; Wydooghe L; Van Duppen D; Seuntjens L; Van der Stuyft P
Ned Tijdschr Geneeskd; 2001 Feb; 145(8):361-6. PubMed ID: 11257816
[TBL] [Abstract][Full Text] [Related]
7. Achieving vascular risk factor targets: a survey of a London general practice.
Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
[TBL] [Abstract][Full Text] [Related]
8. [Inadequate management of dyslipidaemic patients in France. Results of the Odyssée study].
Ferrières J; Elbaz M; Maupas E; Carriè D; Puel J
Arch Mal Coeur Vaiss; 2004 Mar; 97(3):187-93. PubMed ID: 15106741
[TBL] [Abstract][Full Text] [Related]
9. Follow-up in a lipid clinic improves the management of risk factors in cardiovascular disease patients.
Gavish D; Leibovitz E; Elly I; Shargorodsky M; Zimlichman R
Isr Med Assoc J; 2002 Sep; 4(9):694-7. PubMed ID: 12440233
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in risk factor control of treated hypertensives: a national primary healthcare-based study in Sweden.
Journath G; Hellénius ML; Petersson U; Theobald H; Nilsson PM;
Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):258-62. PubMed ID: 18525379
[TBL] [Abstract][Full Text] [Related]
11. Increase in lipid-lowering treatment rates among TRICARE beneficiaries: a population-based study.
Devine J; Linton A; Mistry H; Napier J; Trice S; Bacon T
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):891-9. PubMed ID: 19634117
[TBL] [Abstract][Full Text] [Related]
12. Consequences of using different methods to assess cardiovascular risk in primary care.
Fornasini M; Brotons C; Sellarès J; Martinez M; Galán ML; Sáenz I; da Pena JM
Fam Pract; 2006 Feb; 23(1):28-33. PubMed ID: 16243952
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
Udawat H; Goyal RK
Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk.
Rafter N; Connor J; Hall J; Jackson R; Martin I; Parag V; Vander Hoorn S; Rodgers A
N Z Med J; 2005 Oct; 118(1223):U1676. PubMed ID: 16224500
[TBL] [Abstract][Full Text] [Related]
15. The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care--cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record.
Rabinowitz I; Tamir A
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):56-62. PubMed ID: 15703507
[TBL] [Abstract][Full Text] [Related]
16. [Cost of cardiovascular risk factor prevention in middle-aged French men. The PRIME study].
Marques-Vidal P; Arveiler D; Amouyel P; Ducimetière P; Ferrières J
Rev Epidemiol Sante Publique; 2001 Dec; 49(6):541-9. PubMed ID: 11845103
[TBL] [Abstract][Full Text] [Related]
17. [Cardiovascular risk factors and prevention in women: similarities and differences].
Sclavo M
Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880
[TBL] [Abstract][Full Text] [Related]
18. Growth in use of lipid-lowering therapies: are we targeting the right patients?
Dubois RW; Alexander CM; Wade S; Mosso A; Markson L; Lu JD; Nag S; Berger ML
Am J Manag Care; 2002 Oct; 8(10):862-7. PubMed ID: 12395954
[TBL] [Abstract][Full Text] [Related]
19. Coronary risk estimates and decisions on lipid-lowering treatment in primary prevention: comparison between general practitioners, internists, and cardiologists.
Vancheri F; Strender LE; Montgomery H; Skånér Y; Backlund LG
Eur J Intern Med; 2009 Oct; 20(6):601-6. PubMed ID: 19782921
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of lipid-lowering treatment according to lipid level.
Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
